Polyunsaturated Fatty Acids Interactions and Oxidative Stress Disorders
AssigneesRutgers, The State of New Jersey, Rowan University
InventorsT. P. Stein, Bernd W. Spur, George W. Lambert, Sue X. Ming, Ana Rodriguez
Life of this patent
Estimating the term…
Abstract
This invention relates to the identification and treatment of the effects of products derived from oxidative pathways for polyunsaturated fatty acid (PUFA) metabolism, i.e., oxidative stress in a patient by monitoring the metabolism of DHA or by administering DHA.
Claims21
1-4. (canceled)
A method for the diagnosis of oxidative stress related disorders in a subject comprising:
- (a) collecting a sample of urine from the subject;
- (b) determining the level of polyunsaturated fatty acid metabolites present in the urine;
- and
- (c) normalizing the level of polyunsaturated fatty acid metabolites present in the urine to urinary creatinine to obtain a normalized level of polyunsaturated fatty acid metabolites,
- wherein a normalized level of polyunsaturated fatty acid metabolites above a predetermined amount is indicative of an oxidative stress related disorder.
A method for the diagnosis of oxidative stress related disorders in a subject comprising:
- (a) determining a baseline level of polyunsaturated fatty acid metabolites present in the subject;
- (b) administering a composition comprising polyunsaturated fatty acids to the subject;
- (c) determining a second level of polyunsaturated fatty acid metabolites present in the subject at a predetermined time after administration of the composition comprising polyunsaturated fatty acids to the subject;
- (d) determining the change in the baseline level and second level of polyunsaturated fatty acid metabolites present in the subject;
- wherein, the change in the level of polyunsaturated fatty acid metabolites greater than a predetermined amount indicates that the subject is afflicted with an oxidative stress related disorder.
A method for the diagnosis of oxidative stress related disorders in a subject comprising:
- (a) determining a baseline level of polyunsaturated fatty acid metabolites present in the subject;
- (b) administering a composition comprising polyunsaturated fatty acids to the subject;
- (c) inducing an oxidative stress in the subject at a predetermined time after administration of the composition comprising polyunsaturated fatty acids to the subject;
- (d) determining a second level of polyunsaturated fatty acid metabolites present in the subject at a predetermined time after inducing an oxidative stress in the subject;
- (e) determining the change in the baseline level and second level of polyunsaturated fatty acid metabolites present in the subject;
- wherein, the change in the level of polyunsaturated fatty acid metabolites greater than a predetermined amount indicates that the subject is afflicted with an oxidative stress related disorder.
Dependencies are inferred from the claim text.